In humans, the success rate of BMT across major histocompatibility complex (MHC) barriers is lowered by graft-versus-host disease (GvHD), graft rejection and incomplete T-cell recovery. To prevent GvHD, we attempted to minimize the contamination of bone marrow cells (BMCs) with T cells from the peripheral blood when donor BMCs were collected, finally establishing a new 'Perfusion Method' using cynomolgus monkeys. There was significantly less contamination of BMCs with T cells in this method (o6%) than in the conventional 'Aspiration Method' (420%) consisting of multiple aspirations of BMCs from the iliac crest. Using radio-sensitive and chimerism-resistant MRL/lpr mice, we also established a new method for allogeneic (allo) BMT and organ allografts. In this method, whole BMCs, containing a small number of T cells and mesenchymal stem cells (MSCs), were directly injected into the bone marrow cavity (intrabone marrow [IBM]-BMT). MRL/lpr mice treated with IBM-BMT survived more than 2 years without showing the symptoms of autoimmune diseases. IBM-BMT thus has several advantages: (i) no GvHD develops even if T cells are not depleted from BMCs; (ii) no graft failure occurs even if the dose of radiation as the conditioning regimen for allo BMT is reduced to 5Gy Â 2; (iii) hemopoietic recovery is rapid; and (iv) the restoration of T-cell functions is quick and complete even in donorrecipient combinations across MHC barriers. We believe that these strategies for allo BMT and organ allografts herald a new era in transplantation, and that they would be helpful in allogeneic HSCT of autoimmune diseases. Bone Marrow Transplantation (2003) 32, S73-S75. doi:10.1038/sj.bmt.1703948 Keywords: intrabone marrow injection; autoimmune disease; organ transplantation
Summary:
In humans, the success rate of BMT across major histocompatibility complex (MHC) barriers is lowered by graft-versus-host disease (GvHD), graft rejection and incomplete T-cell recovery. To prevent GvHD, we attempted to minimize the contamination of bone marrow cells (BMCs) with T cells from the peripheral blood when donor BMCs were collected, finally establishing a new 'Perfusion Method' using cynomolgus monkeys. There was significantly less contamination of BMCs with T cells in this method (o6%) than in the conventional 'Aspiration Method' (420%) consisting of multiple aspirations of BMCs from the iliac crest. Using radio-sensitive and chimerism-resistant MRL/lpr mice, we also established a new method for allogeneic (allo) BMT and organ allografts. In this method, whole BMCs, containing a small number of T cells and mesenchymal stem cells (MSCs), were directly injected into the bone marrow cavity (intrabone marrow [IBM]-BMT). MRL/lpr mice treated with IBM-BMT survived more than 2 years without showing the symptoms of autoimmune diseases. IBM-BMT thus has several advantages: (i) no GvHD develops even if T cells are not depleted from BMCs; (ii) no graft failure occurs even if the dose of radiation as the conditioning regimen for allo BMT is reduced to 5Gy Â 2; (iii) hemopoietic recovery is rapid; and (iv) the restoration of T-cell functions is quick and complete even in donorrecipient combinations across MHC barriers. We believe that these strategies for allo BMT and organ allografts herald a new era in transplantation, and that they would be helpful in allogeneic HSCT of autoimmune diseases. We have previously shown, using various autoimmuneprone mice (except for MRL/lpr mice), that conventional allo BMT can be used to prevent and treat a range of autoimmune diseases. [1] [2] [3] We have found that the MRL/lpr mouse, an animal model for autoimmune diseases, is a suitable model for establishing a safe new strategy for allogeneic BMT, since the MRL/lpr mouse itself is radiosensitive (8.5 Gy), while the abnormal hemopoietic stem cells of the MRL/lpr mouse are radioresistant (48.5 Gy); conventional BMT (8.5 Gy plus allo BMT) has a transient effect on autoimmune diseases, which regularly recur 3 months after the BMT. 4 To prevent the recurrence of autoimmune diseases in the MRL/lpr mice, we carried out BMT plus bone grafts to replace not only the hemopoietic cells but also the stromal cells with donor cells. This is because there is a major histocompatibility complex (MHC) restriction between pluripotent hemopoietic stem cells (P-HSCs) and stromal cells. 5 MRL/lpr mice that had been irradiated (8.5 Gy) and then reconstituted with C57BL/6 bone marrow cells (BMCs) plus bone grafts to recruit donor stromal cells survived more than 1 year. 6 Although we found that allo BMT plus bone grafts could prevent the development of autoimmune diseases in MRL/ lpr mice, this strategy (8.5 Gy /bone/BMT) was found to be not beneficial for the treatment of florid autoimmune diseases in MRL/lpr mice. MRL/lpr mice with small amounts of proteinuria (o+) can endure 8.5 Gy irradiation, whereas MRL/lpr mice with greater degrees of proteinuria (X++) are more radiosensitive and are unable to withstand 8.5 Gy irradiation because of uremic enterocolitis. We therefore devised a new method (fractionated radiation) that reduces acute radiation injury, and it therefore reduced the side effects of radiation and prevented graft rejection.
It is well known that tolerance can be easily induced when the antigen is portal venously (PV) injected into the liver. Therefore, we next attempted to induce donor-specific tolerance by injecting BMCs (containing both P-HSCs and mesenchymal stem cells (MSCs)) from the PV.
As shown in Figure 1 , the survival rate of recipients treated with 5.5 Gy Â 2+ PV-BMT was 70%, whereas all recipients treated with 5.5 Gy Â 2+ IV-BMT died within 200 days after the treatment. All recipients treated with 5.5 Gy Â 2+PV-BMT + IV-BMT survived for more than 350 days, indicating that additional IV-BMT is helpful for successful engraftment. 7 When stromal cell-removed BMCs were injected from the PV, the survival rate of the recipients was markedby reduced, indicating the crucial role of stormal cells in the successful engraftment. 8 Based on these findings, we next attempted to inject whole BMCs (including MSCs) directly into the bone marrow cavity. As shown in Figure 1 , recipients treated with intrabone marrow (IBM)-BMT showed markedly better survival rates even when the radiation dose was reduced to 5 Gy Â 2.
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A new strategy for organ allografts and regeneration therapy
We have previously shown that the combination of organ allografts and BMT from the same donors prevents rejection. 10, 11 However, this method was not applicable to humans because of lethal levels of irradiation, and allogeneic BMT in humans has several other problems such as GvHD. As described here, we have recently found that 'PV-BMT' is better than 'IV-BMT'. 7 Accordingly, we attempted skin grafts using 'PV-BMT'.
A skin allograft survival rate of 100% can be obtained with sublethal irradiation (7 Gy) followed by 'PV-BMT'. 12 The recipient mice showed fully allogeneic chimerism, and spleen cells from the recipients showed tolerance to both donor-and host-type MHC determinants in the assays for mixed lymphocyte reaction and generation of cytotoxic T-lymphocytes (CTLs). This method was found to be applicable to pancreas allografts. 13 This simple method should be applicable to human organ allografts. We next compared the effects of 'IBM-BMT' on the induction of tolerance with the effects of 'PV-BMT'. 'IBM-BMT' was found to be more effective in inducing tolerance than 'PV-BMT', since the radiation dose could be reduced to 4.5 Gy Â 2 ( Figure 2) .
We have very recently found using tight-skinned (TsK) mice 14 that IBM-BMT can be used to treat not only scleroderma but also emphysema in TsK mice (submitted for publication). In addition, we have found that IBM-BMT can be used to prevent and treat osteoporosis in SAMP6 mice. 15 We therefore believe that this method (IBM-BMT in conjunction with the Perfusion Method) will become a powerful new strategy for the treatment of various intractable diseases. Furthermore, we believe that this method will become a valuable strategy in regeneration therapy for injured organs and tissues (osteoporosis, emphysema, myocardial infarction, cerebral infarction, Alzheimer's disease, etc), since IBM-BMT can efficiently reconstitute the recipient with both donor-derived hemopoietic stem cells and MSCs. 
